Glutathione dosing in research and supplementation protocols

Glutathione dose ranges in the published literature span two orders of magnitude depending on delivery route. IV clinic protocols dose at the gram level per session; oral supplementation at the hundreds of milligrams per day; liposomal in the middle. The dose-response evidence is uneven across routes — most-mature for IV plasma-pharmacokinetics, least-mature for liposomal intracellular endpoints.

IV glutathione doses

Published IV glutathione protocols cluster around three dose tiers:

• Low-tier (600-1200 mg per session). Common for routine wellness protocols. Plasma C-max elevation is reliable; intracellular effects at this dose tier are modest in the published data.
• Mid-tier (1500-2500 mg per session). Common in published clinical research protocols. Plasma C-max higher and sustained longer. The published intracellular-effect data at this tier is more substantial but still variable.
• High-tier (3-5 g per session). Used in specific clinical-research contexts; less common in routine wellness protocols. Cellular-uptake transporter saturation becomes more relevant at this dose tier.

Session frequency varies from once weekly to once monthly. The cellular-effect sustainability across between-session intervals is the key parameter that the published research has not fully resolved.

Oral glutathione doses

Oral glutathione supplementation protocols range from 250-1000 mg/day. The dose-response is approximately linear for plasma glutathione elevation in the lower range and plateaus at higher doses as gut peptidase capacity becomes overwhelmed.

Typical published research protocols:

• 250 mg twice daily — common entry-level protocol. Plasma effect modest.
• 500 mg twice daily — middle of the published dose range. Plasma effect more reliable.
• 1000 mg daily, divided — upper range of typical oral protocols. Plasma effect more substantial but gut hydrolysis still a major pharmacokinetic loss.

Liposomal glutathione doses

Liposomal glutathione protocols typically range 200-500 mg/day. The bioavailability improvement vs unencapsulated oral allows lower doses to achieve comparable plasma C-max. Common protocols:

• 200 mg daily — entry-level liposomal protocol.
• 300-500 mg daily, often divided morning + evening — middle of the published dose range.

The published intracellular-effect data for liposomal glutathione is less mature than for IV or oral. Most liposomal-glutathione research has been bioavailability-focused (plasma C-max comparisons) rather than intracellular-endpoint focused.

The NAC precursor alternative dose

N-acetylcysteine supplementation protocols range from 600-1800 mg/day. Published dose-finding research shows reliable intracellular glutathione elevation at 600-1200 mg/day in healthy adults. NAC is rapidly absorbed orally, metabolised to cysteine, and used as the rate-limiting precursor for endogenous glutathione synthesis.

The cost-per-mg-delivered for NAC is substantially lower than any glutathione-supplementation route. For the goal of raising intracellular glutathione, NAC is often the more cost-effective strategy per the published research.

Duration considerations

Glutathione-supplementation protocols in the published research range from acute single-dose pharmacokinetic studies to chronic 6-12 month observational studies. The endpoints scale with duration:

• Single-dose acute studies. Plasma pharmacokinetics, time-to-peak, area-under-curve. Limited to PK endpoints.
• 2-4 week studies. Plasma steady-state, modest biomarker changes (red-cell glutathione, oxidative-stress markers).
• 3-6 month studies. Sustained biomarker changes, some intermediate clinical endpoints.
• 6-12 month studies. Longer-term observational research; few RCTs at this duration.

Protocol summary

Further reading

• Glutathione research-overview.
• Glutathione delivery routes.
• Glutathione mechanism deep-dive.
• Free reconstitution calculator.

Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.